Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.